Ranabir SinhaRoy

1.6k total citations
13 papers, 593 citations indexed

About

Ranabir SinhaRoy is a scholar working on Cellular and Molecular Neuroscience, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Ranabir SinhaRoy has authored 13 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cellular and Molecular Neuroscience, 12 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Oncology. Recurrent topics in Ranabir SinhaRoy's work include Neuropeptides and Animal Physiology (12 papers), Diabetes Treatment and Management (12 papers) and Peptidase Inhibition and Analysis (9 papers). Ranabir SinhaRoy is often cited by papers focused on Neuropeptides and Animal Physiology (12 papers), Diabetes Treatment and Management (12 papers) and Peptidase Inhibition and Analysis (9 papers). Ranabir SinhaRoy collaborates with scholars based in United States, Italy and Denmark. Ranabir SinhaRoy's co-authors include Alessandro Pocai, George J. Eiermann, Donald J. Marsh, Paul E. Carrington, Nancy A. Thornberry, Gary G. Chicchi, Ann E. Weber, Joseph K. Wu, Elisabetta Bianchi and Antonello Pessi and has published in prestigious journals such as Diabetologia, Obesity and Biopolymers.

In The Last Decade

Ranabir SinhaRoy

13 papers receiving 582 citations

Peers

Ranabir SinhaRoy
Tomoyuki Odani Japan
Jasminka Dragovic United States
Maria E. Due‐Hansen Denmark
Cynthia Stutsman United States
Hiroki Kumagai Japan
Ayumu Yoshikawa Japan
Edward J. Brady United States
Xiu Quan Du United States
Corey Miller United States
Erik Flodgren Sweden
Tomoyuki Odani Japan
Ranabir SinhaRoy
Citations per year, relative to Ranabir SinhaRoy Ranabir SinhaRoy (= 1×) peers Tomoyuki Odani

Countries citing papers authored by Ranabir SinhaRoy

Since Specialization
Citations

This map shows the geographic impact of Ranabir SinhaRoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranabir SinhaRoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranabir SinhaRoy more than expected).

Fields of papers citing papers by Ranabir SinhaRoy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranabir SinhaRoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranabir SinhaRoy. The network helps show where Ranabir SinhaRoy may publish in the future.

Co-authorship network of co-authors of Ranabir SinhaRoy

This figure shows the co-authorship network connecting the top 25 collaborators of Ranabir SinhaRoy. A scholar is included among the top collaborators of Ranabir SinhaRoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranabir SinhaRoy. Ranabir SinhaRoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Cox, Jason M., Jeffrey T. Kuethe, Ying‐Duo Gao, et al.. (2016). The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(11). 2622–2626. 19 indexed citations
3.
Bianchi, Elisabetta, Paul E. Carrington, Paolo Ingallinella, et al.. (2013). A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorganic & Medicinal Chemistry. 21(22). 7064–7073. 40 indexed citations
4.
Kosinski, Jennifer, James Hubert, Paul E. Carrington, et al.. (2012). The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin. Obesity. 20(8). 1566–1571. 90 indexed citations
5.
Day, Jonathan W., Vasily M. Gelfanov, David L. Smiley, et al.. (2012). Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents. Biopolymers. 98(5). 443–450. 111 indexed citations
6.
Wu, Zhicai, Thomas H. Graham, Andreas Verras, et al.. (2012). Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(4). 1727–1730. 4 indexed citations
7.
8.
Santoprete, Alessia, Elena Capitò, Paul E. Carrington, et al.. (2011). DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives. Journal of Peptide Science. 17(4). 270–280. 53 indexed citations
9.
Abeywickrema, Pravien, Sangita B. Patel, Noel Byrne, et al.. (2010). Expression, purification and crystallization of human prolylcarboxypeptidase. Acta Crystallographica Section F Structural Biology and Crystallization Communications. 66(6). 702–705. 11 indexed citations
10.
Liang, Gui‐Bai, Xiaoxia Qian, Dennis Feng, et al.. (2007). Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 17(7). 1903–1907. 27 indexed citations
11.
Biftu, Tesfaye, Giovanna Scapin, Suresh B. Singh, et al.. (2007). Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Bioorganic & Medicinal Chemistry Letters. 17(12). 3384–3387. 51 indexed citations
12.
Gao, Ying‐Duo, Dennis Feng, Robert P. Sheridan, et al.. (2007). Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(14). 3877–3879. 27 indexed citations
13.
Biftu, Tesfaye, Dennis Feng, Xiaoxia Qian, et al.. (2006). (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 17(1). 49–52. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Odani Breakdown of academic impact, for papers by Jasminka Dragovic Breakdown of academic impact, for papers by Maria E. Due‐Hansen Breakdown of academic impact, for papers by Cynthia Stutsman Breakdown of academic impact, for papers by Hiroki Kumagai Breakdown of academic impact, for papers by Ayumu Yoshikawa Breakdown of academic impact, for papers by Edward J. Brady Breakdown of academic impact, for papers by Xiu Quan Du Breakdown of academic impact, for papers by Corey Miller Breakdown of academic impact, for papers by Erik Flodgren
Rankless by CCL
2026